Vulinacimab (Anti-VEGFR2 / KDR / CD309)

Vulinacimab (Anti-VEGFR2 / KDR / CD309) is a monoclonal antibody targeting VEGFR-2. It has potential anti-angiogenesis and antineoplastic activities and can be used in the research of cancers. MW :145.38 KD.

• Supplier: Selleck Chemicals
• Product #: A3110
• Sku #: A3110-1mg*5